Chemistry - A European Journal, volume 21, issue 39, pages 13646-13665
Evolution of a Unified Strategy for Complex Sesterterpenoids: Progress toward Astellatol and the Total Synthesis of (−)-Nitidasin
2
Present address: Bayer Health Care, Bayer Pharma AG, BPH-GDD-CGEI-MCB-MCII, Müllerstr. 178, 13353 Berlin (Germany).
|
4
Department of Chemistry and Biochemistry, University of California, 607 Charles E Young Drive East, Los Angeles, CA 90095, USA.
|
Publication type: Journal Article
Publication date: 2015-08-20
Journal:
Chemistry - A European Journal
scimago Q1
SJR: 1.058
CiteScore: 7.9
Impact factor: 3.9
ISSN: 09476539, 15213765
PubMed ID:
26300211
General Chemistry
Catalysis
Organic Chemistry
Abstract
Astellatol and nitidasin belong to a subset of sesterterpenoids that share a sterically encumbered trans-hydrindane motif with an isopropyl substituent. In addition, these natural products feature intriguing polycyclic ring systems, posing significant challenges for chemical synthesis. Herein, the evolution of our stereoselective strategy for isopropyl trans-hydrindane sesterterpenoids is detailed. These endeavors included the synthesis of several building blocks, enabling studies toward all molecules of this terpenoid subclass, and of advanced intermediates of our initial route toward a biomimetic synthesis of astellatol. These findings provided the basis for a second-generation and a third-generation approach toward astellatol that eventually culminated in the enantioselective total synthesis of (-)-nitidasin. In particular, a series of substrate-controlled transformations to install the ten stereogenic centers of the target molecule was orchestrated and the carbocyclic backbone was forged in a convergent fashion. Furthermore, the progress toward the synthesis of astellatol is disclosed and insights into some observed yet unexpected diastereoselectivities by detailed quantum-mechanical calculations are provided.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.